Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.St Jude Medical wins FDA approval for connector system
According to the company, the new connector system, which includes the Durata defibrillation lead with the SJ4 connector and the Promote CRT-D with the SJ4 connector, is expected
According to the company, the new connector system, which includes the Durata defibrillation lead with the SJ4 connector and the Promote CRT-D with the SJ4 connector, is expected
The open-label, dose-escalating pivotal trial has been designed to measure durable local complete response at the tumor site. Celsion expects to enroll approximately 100 patients across the US
The study, Revive-diabetes, is a multicenter, randomized, double-blind, placebo-controlled trial and will evaluate the safety and efficacy of avanafil in the treatment of erectile dysfunction (ED) in men
The initial products will be directed to the ovarian cancer biomarker, HE4, which is FDA-cleared for monitoring the progression or recurrence of epithelial ovarian cancer. Fujirebio also grants
Alton Boynton, Northwest Biotherapeutics’s CEO, said: “We are very pleased to have completed another interim financing despite severely adverse general market conditions. We look forward to continuing the
ELISA is provided with all reagents required including a pre-coated microplate eliminating the need for an overnight incubation found with other commercially available kits. Results are achieved in
Total revenues in 2008 were $4.1 billion, an increase of 29% from $3.2 billion in 2007. The company has reported net income of $207 million for the fourth
The study is a multi-center, open-label, randomized two-period crossover comparison of ANX-514 and Taxotere, with a primary endpoint of pharmacokinetic equivalence of ANX-514 and Taxotere and a goal
The application for traditional approval includes 48-week data from two Phase III studies known as Duet-1 and Duet-2. Intelence is currently marketed in the US by Tibotec Therapeutics,
Tigris in-licensed the exclusive worldwide rights to GGTI-2418 from Yale University and the University of South Florida. Edmundo Muniz, president and CEO of Tigris, said: The filing of